Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
Piero Ruggenenti(Mario Negri Institute for Pharmacological Research), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Francesco Scolari(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Annalisa Perna(Mario Negri Institute for Pharmacological Research), Carmine Zoccali(Biogem), Maurizio Salvadori, Francesco Paolo Schena(University of Bari Aldo Moro), G Garini, Giulia Gherardi(Mario Negri Institute for Pharmacological Research)
Cited by 909
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886